May 19, 2023 – CARsgen begins trial of CAR T-cell therapy for gastric cancer

Chinese biotechnology company CARsgen Therapeutics has started a Phase II clinical trial of CT041 in the US, enrolling patients with Claudin18.2 (CLDN18.2) positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ).
CT041 is an autologous chimeric antigen receptor (CAR) T-cell product candidate that targets the CLDN18.2 protein.
The trial will evaluate CT041 in treating individuals with CLDN18.2 positive advanced GC/GEJ who have failed two or more previous lines of systemic treatments.